Protagonist Therapeutics (PTGX) Profit After Tax (2015 - 2026)

Protagonist Therapeutics has reported Profit After Tax for 12 years, with the latest figure at $3.8 million in Q1 2026.

• Quarterly Profit After Tax rose 132.46% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.7 million (down 304.14% YoY) and the FY2025 annual result came in at -$130.1 million, down 147.29% from the prior year.
• Profit After Tax improved to $3.8 million in Q1 2026 per PTGX's latest filing, from -$44.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at $207.3 million in Q1 2024 and troughed at -$44.4 million in Q4 2025.
• A 5-year average of -$3.4 million and a median of -$33.2 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 714.8% in 2024, then slumped 133.71% in 2025.
• Over 5 years, Profit After Tax stood at -$34.2 million in 2022, then surged by 179.94% to $27.3 million in 2023, then soared by 381.7% to $131.7 million in 2024, then plunged by 133.71% to -$44.4 million in 2025, then surged by 108.52% to $3.8 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $3.8 million, -$44.4 million, and -$39.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.